Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Abstract C131: ‘KRAS addiction’ an artifact of 2D culture? Inhibitors of the mut-KRAS NSCLC 3D growth

D. Lynn Kirkpatrick, Roisin Delaney, Geoff Grandjean, Assael Madrigal, Martin Indarte, Mike Scott, Garth Powis

Mol Cancer Ther (2015) 14 (12_Supplement_2): C131.

https://doi.org/10.1158/1535-7163.TARG-15-C131

Published: 01 December 2015

View article titled, Abstract C131: ‘KRAS addiction’ an artifact of 2D culture? Inhibitors of the mut-KRAS NSCLC 3D growth

Journal Articles

Abstract A197: Oncogenic KRAS is dependent on the scaffold protein CNKSR1 for cell growth and signaling.

Nathan T. Ihle, Geoff Grandjean, John Kingston, Shuxing Zhang, Lei Du-Curry, Martin Indarte, Lynn Kirkpatrick, Garth Powis

Mol Cancer Ther (2011) 10 (11_Supplement): A197.

https://doi.org/10.1158/1535-7163.TARG-11-A197

Published: 12 November 2011

View article titled, Abstract A197: Oncogenic KRAS is dependent on the scaffold protein CNKSR1 for cell growth and signaling.

Journal Articles

Abstract C137: Single-walled carbon nanotubes provide a safe and effective means for delivery of siRNA.

Lynn Kirkpatrick, Olga Gliko, Michelle Weiss, Anton Naumov, Bruce Weisman

Mol Cancer Ther (2011) 10 (11_Supplement): C137.

https://doi.org/10.1158/1535-7163.TARG-11-C137

Published: 12 November 2011

View article titled, Abstract C137: Single-walled carbon nanotubes provide a safe and effective means for delivery of siRNA.

Journal Articles

Abstract A213: Topical PHT-427, a dual AKT/PDPK1 PH domain inhibitor, for treatment of primary and metastatic skin cancer.

Emmanuelle Meuillet, Sylvester Moses, Jenny Johnson, Robert Lemos, Mena F. Abdelmelek, Garth Powis, Lynn Kirkpatrick

Mol Cancer Ther (2011) 10 (11_Supplement): A213.

https://doi.org/10.1158/1535-7163.TARG-11-A213

Published: 12 November 2011

View article titled, Abstract A213: Topical PHT-427, a dual AKT/PDPK1 PH domain inhibitor, for treatment of primary and metastatic skin cancer.

Journal Articles

Abstract A199: The plekstrin-homology-domain-containing protein PLEKHA7 is a novel target for selectively inhibiting mutant KRAS colon cancer cell proliferation.

Hei-Cheul Jeung, Galina Kiriakova, Lynn Kirkpatrick, Martin Indarte, Garth Powis

Mol Cancer Ther (2011) 10 (11_Supplement): A199.

https://doi.org/10.1158/1535-7163.TARG-11-A199

Published: 12 November 2011

View article titled, Abstract A199: The plekstrin-homology-domain-containing protein PLEKHA7 is a novel target for selectively inhibiting mutant KRAS colon cancer cell proliferation.

Journal Articles

Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor

Emmanuelle J. Meuillet, Song Zuohe, Robert Lemos, Nathan Ihle, John Kingston, Ryan Watkins, Sylvestor A. Moses, Shuxing Zhang, Lei Du-Cuny, Roy Herbst, Jörg J. Jacoby, Li Li Zhou, Ali M. Ahad, Eugene A. Mash, D. Lynn Kirkpatrick, Garth Powis

Mol Cancer Ther (2010) 9 (3): 706–717.

https://doi.org/10.1158/1535-7163.MCT-09-0985

Published: 09 March 2010

View article titled, Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor

Journal Articles

Abstract C142: Safety of single‐walled carbon nanotubes for delivery of siRNA

Lynn Kirkpatrick, Geoffrey Bartholomeusz, Michelle Weiss, Dima Tsyboulski, Saunab Ghosh, Bruce Weisman

Mol Cancer Ther (2009) 8 (12_Supplement): C142.

https://doi.org/10.1158/1535-7163.TARG-09-C142

Published: 10 December 2009

View article titled, Abstract C142: Safety of single‐walled carbon nanotubes for delivery of siRNA

Journal Articles

Abstract B139: Molecular pharmacology and antitumor activity of PHT‐427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor

Garth Powis, Sylvestor A. Moses, Shuxing Zhang, Lei Du‐Cuny, Zuohe Song, Roy Herbst, Joerg Jacoby, Lynn Kirkpatrick, Eugene Mash, Emmanuelle J. Meuillet

Mol Cancer Ther (2009) 8 (12_Supplement): B139.

https://doi.org/10.1158/1535-7163.TARG-09-B139

Published: 10 December 2009

View article titled, Abstract B139: Molecular pharmacology and antitumor activity of PHT‐427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor

Journal Articles

Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Nathan T. Ihle, Robert Lemos, David Schwartz, Junghwan Oh, Robert J. Halter, Peter Wipf, Lynn Kirkpatrick, Garth Powis

Mol Cancer Ther (2009) 8 (1): 94–100.

https://doi.org/10.1158/1535-7163.MCT-08-0714

Published: 12 January 2009

View article titled, Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Journal Articles

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α

Mei Y. Koh, Taly Spivak-Kroizman, Sara Venturini, Sarah Welsh, Ryan R. Williams, D. Lynn Kirkpatrick, Garth Powis

Mol Cancer Ther (2008) 7 (1): 90–100.

https://doi.org/10.1158/1535-7163.MCT-07-0463

Published: 17 January 2008

View article titled, Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α

Journal Articles

Oncogenic ras predicts lack of response to PX-866, an inhibitor of the phosphatidylinositol-3-kinase pathway in tumor xenograft models.

Nathan Ihle, Robert Lemos, Gordon Mills, Paul Dent, Lynn Kirkpatrick, Garth Powis

Mol Cancer Ther (2007) 6 (11_Supplement): A257.

Published: 01 November 2007

View article titled, Oncogenic ras predicts lack of response to PX-866, an inhibitor of the phosphatidylinositol-3-kinase pathway in tumor xenograft models.

Journal Articles

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase

Garth Powis, Peter Wipf, Stephen M. Lynch, Anne Birmingham, D. Lynn Kirkpatrick

Mol Cancer Ther (2006) 5 (3): 630–636.

https://doi.org/10.1158/1535-7163.MCT-05-0487

Published: 16 March 2006

View article titled, Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase

Journal Articles

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

Nathan T. Ihle, Gillian Paine-Murrieta, Margareta I. Berggren, Amanda Baker, Wendy R. Tate, Peter Wipf, Robert T. Abraham, D. Lynn Kirkpatrick, Garth Powis

Mol Cancer Ther (2005) 4 (9): 1349–1357.

https://doi.org/10.1158/1535-7163.MCT-05-0149

Published: 16 September 2005

View article titled, The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

Journal Articles

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Nathan T. Ihle, Ryan Williams, Sherry Chow, Wade Chew, Margareta I. Berggren, Gillian Paine-Murrieta, Daniel J. Minion, Robert J. Halter, Peter Wipf, Robert Abraham, Lynn Kirkpatrick, Garth Powis

Mol Cancer Ther (2004) 3 (7): 763–772.

https://doi.org/10.1158/1535-7163.763.3.7

Published: 13 July 2004

View article titled, Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Journal Articles

Hypoxia inducible factor-1α as a cancer drug target

Garth Powis, Lynn Kirkpatrick

Mol Cancer Ther (2004) 3 (5): 647–654.

https://doi.org/10.1158/1535-7163.647.3.5

Published: 12 May 2004

View article titled, Hypoxia inducible factor-1α as a cancer drug target

Journal Articles

Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α

Sarah Welsh, Ryan Williams, Lynn Kirkpatrick, Gillian Paine-Murrieta, Garth Powis

Mol Cancer Ther (2004) 3 (3): 233–244.

https://doi.org/10.1158/1535-7163.233.3.3

Published: 16 March 2004

View article titled, Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α

Journal Articles

The Thioredoxin Redox Inhibitors 1-Methylpropyl 2-Imidazolyl Disulfide and Pleurotin Inhibit Hypoxia-induced Factor 1α and Vascular Endothelial Growth Factor Formation

Sarah J. Welsh, Ryan R. Williams, Anne Birmingham, David J. Newman, D. Lynn Kirkpatrick, Garth Powis

Mol Cancer Ther (2003) 2 (3): 235–243.

Published: 01 March 2003

View article titled, The Thioredoxin Redox Inhibitors 1-Methylpropyl 2-Imidazolyl Disulfide and Pleurotin Inhibit Hypoxia-induced Factor 1α and Vascular Endothelial Growth Factor Formation

NARROW

Abstract C131: ‘KRAS addiction’ an artifact of 2D culture? Inhibitors of the mut-KRAS NSCLC 3D growth

Abstract A197: Oncogenic KRAS is dependent on the scaffold protein CNKSR1 for cell growth and signaling.

Abstract C137: Single-walled carbon nanotubes provide a safe and effective means for delivery of siRNA.

Abstract A213: Topical PHT-427, a dual AKT/PDPK1 PH domain inhibitor, for treatment of primary and metastatic skin cancer.

Abstract A199: The plekstrin-homology-domain-containing protein PLEKHA7 is a novel target for selectively inhibiting mutant KRAS colon cancer cell proliferation.

Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor

Abstract C142: Safety of single‐walled carbon nanotubes for delivery of siRNA

Abstract B139: Molecular pharmacology and antitumor activity of PHT‐427 a novel AKT/PDPK1 pleckstrin homology domain inhibitor

Peroxisome proliferator-activated receptor γ agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity

Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α

Oncogenic ras predicts lack of response to PX-866, an inhibitor of the phosphatidylinositol-3-kinase pathway in tumor xenograft models.

Molecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non–small cell lung cancer xenografts

Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling

Hypoxia inducible factor-1α as a cancer drug target

Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α

The Thioredoxin Redox Inhibitors 1-Methylpropyl 2-Imidazolyl Disulfide and Pleurotin Inhibit Hypoxia-induced Factor 1α and Vascular Endothelial Growth Factor Formation

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only